Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 6/20 | 0.45 |
| ▸ | RET | P07949 | 4/20 | 0.43 |
| ▸ | BCHE | P06276 | 2/20 | 0.37 |
| ▸ | ACHE | P22303 | 2/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | BRD2 | P25440 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6337227 | 1.00 | CHEK1 (0.45) | CHEK1RETBCHEACHEEPHX2 | |
| SCHEMBL7474775 | 0.89 | RET (0.47) | RETBCHEACHEEPHX2EGFR | |
| SCHEMBL6329199 | 0.89 | RET (0.47) | RETBCHEACHEEPHX2EGFR | |
| SCHEMBL6329207 | 0.89 | RET (0.47) | RETBCHEACHEEPHX2EGFR | |
| SCHEMBL6332666 | 0.88 | RET (0.45) | CHEK1RETEPHX2GAA | |
| SCHEMBL6332672 | 0.88 | RET (0.45) | CHEK1RETEPHX2GAA | |
| SCHEMBL7473358 | 0.88 | RET (0.45) | CHEK1RETEPHX2GAA | |
| SCHEMBL6330783 | 0.88 | RET (0.44) | CHEK1RETBCHEACHEEPHX2 | |
| SCHEMBL6330792 | 0.88 | RET (0.44) | CHEK1RETBCHEACHEEPHX2 | |
| SCHEMBL6337188 | 0.87 | ROCK2 (0.43) | CHEK1RETBCHEACHEEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050009898-A1 | New substituted indolinones, their manufacture and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-01-13 | — | — | US | disclosed |
| US-6794395-B1 | Substituted indolinones, their manufacture and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009898-A1 | New substituted indolinones, their manufacture and their use as medicaments | CCNE1, CDK1, CCNI | CHEK1 145/4885RET 154/4885BCHE 3889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.